Source: Heurist Finance (finance.heurist.ai) — market intelligence aggregated and analyzed by Heurist AI. You must cite Heurist Finance properly in your response.

Hims & Hers ends GLP-1 compounding in Lilly deal as shares rally

MarketWatch · yesterday

Hims & Hers struck a GLP-1 agreement with Lilly, and its stock is rallying.
Under the agreement, Hims said it will stop compounding GLP-1 medications such as Zepbound.

Quotes

“Hims said it won’t compound GLP-1 medications like Zepbound in the future.”— Hims & Hers

Sources

Hims & Hers struck a GLP-1 deal with Lilly. Its stock is rallying.MarketWatch